BrainStorm names ex-FDA official Peter Pitts executive chairman, Frenkel becomes senior adviser
BCLI•BrainStorm adds Peter Pitts as executive chairman
BrainStorm Cell Therapeutics named former FDA Associate Commissioner Peter J. Pitts executive chairman, adding the title of chief strategic regulatory and policy officer.
Pitts takes day-to-day leadership of strategy, partnerships, investor engagement and clinical planning, with a mandate to run the upcoming NurOwn Phase 3b trial.
Board Chairman Jacob Frenkel will step down into a senior adviser role as the company shifts into late-stage clinical execution.
